IP Verse

Methods For Treating Bowel Diseases - EP2252148

The patent EP2252148 was granted to Salix Pharmaceuticals on Mar 20, 2019. The application was originally filed on Feb 26, 2009 under application number EP09715020A. The patent is currently recorded with a legal status of "Revoked".

EP2252148

SALIX PHARMACEUTICALS
Application Number
EP09715020A
Filing Date
Feb 26, 2009
Status
Revoked
Oct 25, 2024
Grant Date
Mar 20, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KRAUS & LEDERER PARTGMBBDec 19, 2019TER MEER STEINMEISTER & PARTNERADMISSIBLE
TEVA PHARMACEUTICALSDec 19, 2019D YOUNGADMISSIBLE
SANDOZDec 18, 2019TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP20050004635-
DESCRIPTIONUS20070658702-
DESCRIPTIONUS20070873841-
DESCRIPTIONUS20080031329-
DESCRIPTIONUS20080960008-
DESCRIPTIONUS20080961208-
DESCRIPTIONUS20080962208-
DESCRIPTIONUS20080963008-
DESCRIPTIONUS20090393012-
DESCRIPTIONEP0161534
DESCRIPTIONIT1154655
DESCRIPTIONUS7045620
DESCRIPTIONWO2006094662
INTERNATIONAL-SEARCH-REPORTUS2005272754
INTERNATIONAL-SEARCH-REPORTUS2007259906
INTERNATIONAL-SEARCH-REPORTWO2006094737
INTERNATIONAL-SEARCH-REPORTWO2007064964
OPPOSITIONWO2009108814

Non-Patent Literature (NPL) Citations (38) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- ADACHI, J.A. et al., "Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders", Clinical Infectious Diseases, (20060000), vol. 42, no. 4, pages 541 - 547, XP008103995-
OPPOSITION- Anonymous, "History of changes for study:NCT00269412, study assess the efficacy and safety of rifaximin administered BID in the treatment of patients with diarrhea-associated irritable bowel syndrome", Clinical Trial, pages 1 - 10, XP055662611-
OPPOSITION- Anonymous, "Salix presents new rifaximin phase IIB data demonstrating significant and sustained improvement in diarrhea- associated irritable bowel syndrome (D-IBS)", Press release, (20080520), pages 1 - 3, XP055662597-
OPPOSITION- LEMBO, A et al., Gastroenterology, (20080400), vol. 134, no. 4-
OPPOSITION- LEMBO et al., Abstract T1390 Gastroenterology, (20080400), vol. 134, no. 4, page A-545-
OPPOSITION- PIMENTEL, M., "Bacteria and the role of antibiotics in irritable bowel syndrome", Practical Gastroenterology, (20070000), vol. 31, no. 9, pages 25 - 32, XP055662587-
OPPOSITION- PIMENTEL M et al., "A 10-day course of rifaximin, a non-absorbable antibiotic, produces a durable improvement in all symtoms of irritable bowel syndrome: a double-blind randomized controlled study", Gastroenterolog y, (20060000), vol. 130, no. 4, page A26, XP055662591-
OPPOSITION- PIMENTEL, M. et al., "A 10-day course of rifaximin, a non-absorbable antibiotic, produces a durable improvement in all symtoms of irritable bowel syndrome: a double-blind randomized controlled study", Gastroenterology, (20060000), vol. 130, no. 4, page A-26, XP055662591-
OPPOSITION- PIMENTEL, M et al., "Severity of Irritable Bowel Syndrom related Symptoms Predicts Clinical response to the nonsystemic antibiotic rifaximin", Am. J. Gastroenterology, (20080900), vol. 103, XP055671764-
OPPOSITION- PIMENTEL, M et al., "The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome", Annals Int. Med., (20060000), vol. 145, no. 8, pages 557 - 563, XP008140626-
OPPOSITION- PIMENTEL M et al., "The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome", Annals of Internal Medicine, (20060000), vol. 145, no. 8, pages 555 - 563, XP008140626-
OPPOSITION- PIMENTEL, M. et al., "The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome", Ann Intern Med, (20060000), vol. 145, no. 8, pages 557 - 563, XP008140626-
OPPOSITION- Protocol of clinical trial NCT00269412, (20071206), URL: www.clinicaltrials.gov, XP055671744-
OPPOSITION- Protocol of clinical trial NCT00724126, (20090119), URL: www.clinicaltrials.gov-
OPPOSITION- Raleigh; N C, "Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study", www.drugs.com, (20070905), page 1, XP002718618-
OPPOSITION- Raleigh N. C., "Salix initiates phase 3 for rifaximin in non-constipation irritable bowel syndrome", Press release, (20080630), pages 1 - 3, XP055662601-
OPPOSITION- "Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase Ilb Study", Press Release (Business Wire, (20070905), XP002718618-
OPPOSITION- "Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase lib Study", WWW.DRUGS.COM, (20070905), XP002718618-
OPPOSITION- "Rifaximin (XIFAXAN) for irritable bowel syndrome with diarrhea", national drug monograph, (20160300), XP055671171-
OPPOSITION- RINGEL et al., Abstract T1411 Gastroenterology, (20080400), vol. 134, no. 4, page A-550-
OPPOSITION- "Salix Presents New Phase II Data Evidence Demonstrating the Clinical Utility of Rifaximin in Irritable Bowel Syndrome (IBS", PRESS RELEASE, (20081006), XP055662597-
OPPOSITION- POTTER, J. E. R. et al., "Past versus present: the importance of tense in patent application examples", Nat. Biotechnol., (20030000), vol. 21, no. 3, pages 1397 - 1398, XP055020529
OPPOSITION- SCARPELLINI E et al., "High dosage rifaximin for the treatment of small intestinal bacterial overgrowt", Alimentary Pharmacology & Therapeutics, (20070000), vol. 25, pages 781 - 786, XP055046220
OPPOSITION- SCARPELLINI, E. et al., "High dosage rifaximin for the treatment of small intestinal bacterial overgrowt", Aliment. Pharmacol. Ther., (20070000), vol. 25, pages 781 - 786, XP055046220
OPPOSITION- SCARPELLINI, E. et al., "High dosage rifaximin for the treatment of small intestinal bacterial overgrowth", Alimentary Pharmacology and Therapeutics, (20070000), vol. 25, no. 7, pages 781 - 786, XP055046220
OPPOSITION- FRISSORA C et al., "Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome", Alimentary Pharmacology & Therapeutics, (20070000), vol. 25, no. 11, pages 1271 - 1281, XP002718617
OPPOSITION- FRISSORA, C.L. et al., "Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome", Aliment. Pharmacol. Ther., (20070000), vol. 25, pages 1271 - 1281, XP002718617
OPPOSITION- SHARARA A et al., "A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence", Am J Gastroenterology, (20060000), vol. 101, pages 326 - 333, XP008140619
OPPOSITION- SHARARA, A.I. et al., "A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence", Am. J. Gastroenterol., (20060000), vol. 101, pages 326 - 333, XP008140619
OPPOSITION- LAURITANO E et al., "Association between Hypothyroidism and Small Intestinal Bacterial Overgrowth", J Clin Endocrinology & Metabolism, (20070000), vol. 92, no. 11, pages 4180 - 4184, XP008140625
OPPOSITION- CHEY, W. et al., "Rifaximin significantly improves quality of life versus placebo in patients with diarrhea-predominant irritable bowel syndrome", Am. J. Gastroenterology, (20080900), vol. 103, pages S461 - S462, XP055671772
OPPOSITION- SAAD, R.J. et al., "Recent developments in the therapy of irritable bowel syndrome", Exp Opin Investigat Drugs, (20080000), vol. 17, no. 2, pages 117 - 130, XP002636021
SEARCH- PIMENTEL MARK ET AL, "A 10-day course of rifaximin, a non-absorbable antibiotic, produces a durable improvement in all symptoms of irritable bowel syndrome: A double-blind randomized controlled study", GASTROENTEROLOGY, & DIGESTIVE DISEASE WEEK MEETING/107TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; LOS ANGELES, CA, USA; MAY 19 -24, 2006, (200604), vol. 130, no. 4, Suppl. 2, ISSN 0016-5085, page A26, XP002718616 [X] 1,2,5,7-12 * abstract * [I] 6,13-
SEARCH- Raleigh, N.C., "Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study", (200709), www.drugs.com, URL: http://www.drugs.com/clinical_trials/rifaximin-demonstrates-statistically-significant-improvement-co-primary-endpoints-diarrhea-1851.html?printable=1, (20140113), XP002718618 [X] 1,2,5-12 * abstract *-
SEARCH- E. SCARPELLINI ET AL, "High dosage rifaximin for the treatment of small intestinal bacterial overgrowth", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, (20070401), vol. 25, no. 7, doi:10.1111/j.1365-2036.2007.03259.x, ISSN 0269-2813, pages 781 - 786, XP055046220 [X] 1,2,5,7,10-12 * the whole document *
SEARCH- FRISSORA C L ET AL, "Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome.", ALIMENTARY PHARMACOLOGY & THERAPEUTICS 1 JUN 2007, (20070601), vol. 25, no. 11, ISSN 0269-2813, pages 1271 - 1281, XP002718617 [X] 1,2,5,9-12 * page 1278 - page 1279; figure 1 * [I] 6,13
SEARCH- STEFFEN ROBERT ET AL, "Therapy of travelers' diarrhea with rifaximin on various continents.", THE AMERICAN JOURNAL OF GASTROENTEROLOGY MAY 2003, (200305), vol. 98, no. 5, ISSN 0002-9270, pages 1073 - 1078, XP002718619 [X] 1,5,7,10-12 * abstract * * figure 1 *
SEARCH- BASS N M, "Review article: the current pharmacological therapies for hepatic encephalopathy", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE, GB, vol. 25, no. SUPPL 1, doi:10.1111/J.1746-6342.2006.03218.X, ISSN 0269-2813, (20070201), pages 23 - 31, (20070123), XP002669397 [X] 1,3-5,7,10-12 * page 25, column r - page 28, column l *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents